Search

Your search keyword '"Brunt, M."' showing total 128 results
Start Over Author "Brunt, M."
128 results on '"Brunt, M."'

5. Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’

Author

Bachelot, T., primary, Dalenc, F., additional, Chabaud, S., additional, Cottu, P., additional, Allouache, D., additional, Brain, E., additional, Jacquin, J.-P., additional, Grenier, J., additional, Venat Bouvet, L., additional, Brunt, M., additional, Campone, M., additional, Del Piano, F., additional, Debled, M., additional, Hardy Bessard, A.-C., additional, Giacchetti, S., additional, Bliss, J., additional, Canon, J.-L., additional, Lemonnier, J., additional, Cameron, D., additional, and André, F., additional

Published
2021
Full Text
View/download PDF

6. Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer

Author

Bachelot, T., primary, Dalenc, F., additional, Chabaud, S., additional, Cottu, P., additional, Allouache, D., additional, Brain, E., additional, Jacquin, J-P., additional, Grenier, J., additional, Bouvet, L. Venat, additional, Brunt, M., additional, Campone, M., additional, Del Piano, F., additional, Debled, M., additional, Bessard, A-C. Hardy, additional, Giacchetti, S., additional, Bliss, J., additional, Canon, J-L., additional, Lemonnier, J., additional, Cameron, D., additional, and André, F., additional

Published
2021
Full Text
View/download PDF

7. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Author

Corrie, PG, Marshall, A, Nathan, PD, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, CG, Marples, M, Danson, SJ, Marshall, E, Houston, SJ, Board, RE, Waterston, AM, Nobes, JP, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, PM, Ottensmeier, CH, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, EO, Harman, C, Weiss, M, Myers, KA, Chhabra, A, Rodwell, SH, Dunn, JA, Middleton, MR, AVAST-M Investigators, Nathan, P, Dziewulski, P, Holikova, S, Panwar, U, Thomas, A, Corrie, P, Sirohi, B, Kelly, C, Middleton, M, Danson, S, Lester, J, Ajaz, M, Houston, S, Board, R, Eaton, D, Waterston, A, Nobes, J, Loo, S, Gray, G, Stubbings, H, Marsden, J, Patel, P, Ottensmeier, C, Dega, R, Herbert, C, Price, C, Brunt, M, Scott-Brown, M, Hamilton, J, Hayward, RL, Smyth, J, Woodings, P, Nayak, N, Burrows, L, Wolstenholme, V, Wagstaff, J, Nicolson, M, Wilson, A, Barlow, C, Scrase, C, Podd, T, Gonzalez, M, Stewart, J, Highley, M, Grumett, S, Talbot, T, Nathan, K, Coltart, R, and Gee, B

Subjects
Oncology, 0301 basic medicine, Male, Skin Neoplasms, Time Factors, medicine.medical_treatment, Dermatologic Surgical Procedures, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Clinical endpoint, Melanoma, Aged, 80 and over, Manchester Cancer Research Centre, Hazard ratio, adjuvant therapy, Hematology, Middle Aged, Corrigenda, Vascular endothelial growth factor, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Adjuvant, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Bevacizumab, Adolescent, bevacizumab, Disease-Free Survival, Drug Administration Schedule, RC0254, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Adjuvant therapy, melanoma, Humans, Watchful Waiting, Survival analysis, Aged, Neoplasm Staging, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Original Articles, medicine.disease, Survival Analysis, Confidence interval, 030104 developmental biology, chemistry, Mutation, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

Background Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence. Patients and methods Patients with resected AJCC stage IIB, IIC and III cutaneous melanoma were randomised to receive either adjuvant bevacizumab (7.5 mg/kg i.v. 3 weekly for 1 year) or standard observation. The primary end point was detection of an 8% difference in 5-year overall survival (OS) rate; secondary end points included disease-free interval (DFI) and distant metastasis-free interval (DMFI). Tumour and blood were analysed for prognostic and predictive markers. Results Patients (n=1343) recruited between 2007 and 2012 were predominantly stage III (73%), with median age 56 years (range 18–88 years). With 6.4-year median follow-up, 515 (38%) patients had died [254 (38%) bevacizumab; 261 (39%) observation]; 707 (53%) patients had disease recurrence [336 (50%) bevacizumab, 371 (55%) observation]. OS at 5 years was 64% for both groups [hazard ratio (HR) 0.98; 95% confidence interval (CI) 0.82–1.16, P = 0.78). At 5 years, 51% were disease free on bevacizumab versus 45% on observation (HR 0.85; 95% CI 0.74–0.99, P = 0.03), 58% were distant metastasis free on bevacizumab versus 54% on observation (HR 0.91; 95% CI 0.78–1.07, P = 0.25). Forty four percent of 682 melanomas assessed had a BRAFV600 mutation. In the observation arm, BRAF mutant patients had a trend towards poorer OS compared with BRAF wild-type patients (P = 0.06). BRAF mutation positivity trended towards better OS with bevacizumab (P = 0.21). Conclusions Adjuvant bevacizumab after resection of high-risk melanoma improves DFI, but not OS. BRAF mutation status may predict for poorer OS untreated and potential benefit from bevacizumab. Clinical Trial Information ISRCTN 81261306; EudraCT Number: 2006-005505-64

Published
2018

8. The effect of combustion chamber design on the combustion rate in an SI engine

Author

Brunt, M. F. J.

Subjects
621.43, Ignition, Internal combustion, Combustion engines, Combustion
Abstract

The effect of combustion chamber design on combustion rate has been investigated experimentally and theoretically. The experimental work concentrated on the measurement of cylinder pressure and flame speed using a piezo-electric pressure transducer and multiple ionisation probes together with a data acquisition/processing system. A total of twenty one chamber designs of varying shape, compression ratio and spark plug arrangement were tested over a range of operating conditions on a single cylinder S.I. engine. The pressure data were analysed to obtain values of pressure rise rate, cyclic dispersion and combustion (mass burn) rate whilst the ionisation data were processed to yield flame travel angles and flame dispersion. The results obtained show that for a given compression ratio, the flame speed is not significantly affected by chamber design. In contrast, the combustion rate and pressure parameters are highly dependent on the chamber design; more compact arrangements giving higher combustion rates and reduced cyclic dispersion. A computer simulation model of the compression, combustion and expansion phases of the engine cycle was developed to predict the effects of the combustion chamber design parameters. Based on the experimental results, the model assumes that the ratio of laminar to turbulent burning velocity is independent of chamber design. The influence of chamber shape on the burnt volume, flame front surface area and heat transfer surface areas is modelled using a simple but effective geometric integration technique. This technique allows an infinite variation of the design parameters to be specified for a large range of chamber shapes with a minimum of input data being required. The model predicts that chamber design does have a major effect on combustion rate and cylinder pressure but shows that the influence of individual design is highly dependent on the setting of all other parameters. The effect of squish area is shown to be due to it changing the compactness of the chamber, optimum squish area being about 50% for conventional engines with higher areas being suited to higher compression ratio designs. Spark plug arrangement is predicted to be the most effective way of controlling the combustion rate with a single centrally located spark plug or alternatively, dual spark plugs, giving large increases in combustion rate. Computer model predictions have been compared directly with experimental results obtained in this study and with experimental results reported by two other independent workers. Good agreement was obtained thereby giving support to the assumption of the flame speed being unaffected 'by chamber design. The model was also used to predict squish velocities in fired engines. The results show that the velocities and, in particular the reverse squish, can be significantly modified by the combustion process with a strong dependence on ignition timing being evident. The predictive model has been modified to yield a heat release program capable of analysing experimental pressure time data to predict combustion rate, flame speed, turbulent burning velocity and many other variables. The predicted flame speeds were in good agreement with corresponding experimental values obtained from ionisation probes. In conclusion, the study has confirmed the importance of combustion chamber design as a means of improving the combustion rate but has shown that the flame speed is not affected by chamber shape (i.e. squish). The semi-empirical simulation model has been shown to predict the effects of the chamber design parameters to an acceptable degree of accuracy.

Published
1980

12. LONG TERM FOLLOW-UP OF FoRT: A PHASE 3 MULTI-CENTER PROSPECTIVE RANDOMIZED TRIAL OF RADIATION THERAPY FOR FOLLICULAR AND MARGINAL ZONE LYMPHOMA

Author

Hoskin, P., primary, Kirkwood, A., additional, Popova, B., additional, Schofield, O., additional, Brammer, C., additional, Robinson, M., additional, Brunt, M., additional, Krishnaswamy, M., additional, Illidge, T., additional, Gallop-Evans, E., additional, Syndikus, I., additional, and Clifton-Hadley, L., additional

Published
2019
Full Text
View/download PDF

15. 148P Phase III study of everolimus or placebo in addition to adjuvant hormone therapy for high risk early breast cancer: Subgroup analysis of the UCBG UNIRAD trial

Author

Cottu, P.H., Dalenc, F., Chabaud, S., Allouache, D., Cameron, D., Jacquin, J-P., Grenier, J., Barthelemy, P., Brunt, M., Kaluzinski, L., Mailliez, A., Legouffe, E., Hardy-Bessard, A-C., Giacchetti, S., Reynier, M.A. Mouret, Canon, J-L., Bliss, J., Lemonnier, J., André, F., and Bachelot, T.

Published
2021
Full Text
View/download PDF

16. The SAGES Fundamental Use of Surgical Energy program (FUSE): history, development, and purpose

Author

Fuchshuber, P., primary, Schwaitzberg, S., additional, Jones, D., additional, Jones, S. B., additional, Feldman, L., additional, Munro, M., additional, Robinson, T., additional, Purcell-Jackson, G., additional, Mikami, D., additional, Madani, A., additional, Brunt, M., additional, Dunkin, B., additional, Gugliemi, C., additional, Groah, L., additional, Lim, R., additional, Mischna, J., additional, and Voyles, C. R., additional

Published
2017
Full Text
View/download PDF

20. Abstract PD5-06: Effects of perioperative lapatinib in early HER2+ breast cancer - The UK EPHOS-B trial (CRUK/08/002)

Author

Bundred, N, primary, Cameron, D, additional, Kalaitzaki, E, additional, Morley, R, additional, Cramer, A, additional, Webster-Smith, M, additional, Narayanan, S, additional, Brunt, M, additional, Horgan, K, additional, Hanby, A, additional, Ooi, J, additional, Hong, A, additional, Naik, J, additional, Evans, A, additional, Shaaban, A, additional, and Bliss, J, additional

Published
2016
Full Text
View/download PDF

22. The SAGES Fundamental Use of Surgical Energy program (FUSE): history, development, and purpose.

Author

Fuchshuber, P., Schwaitzberg, S., Jones, D., Jones, S. B., Feldman, L., Munro, M., Robinson, T., Purcell-Jackson, G., Mikami, D., Madani, A., Brunt, M., Dunkin, B., Gugliemi, C., Groah, L., Lim, R., Mischna, J., and Voyles, C. R.

Subjects
ELECTROSURGERY, OPERATING rooms, SURGICAL education, PATIENT safety, SURGICAL complications
Abstract

Background: Adverse events due to energy device use in surgical operating rooms are a daily occurrence. These occur at a rate of approximately 1-2 per 1000 operations. Hundreds of operating room fires occur each year in the United States, some causing severe injury and even mortality. The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) therefore created the first comprehensive educational curriculum on the safe use of surgical energy devices, called Fundamental Use of Surgical Energy (FUSE). This paper describes the history, development, and purpose of this important training program for all members of the operating room team.Methods: The databases of SAGES and the FUSE committee as well as personal photographs and documents of members of the FUSE task force were used to establish a brief history of the FUSE program from its inception to its current status.Results: The authors were able to detail all aspects of the history, development, and national as well as global implementation of the third SAGES Fundamentals Program FUSE.Conclusions: The written documentation of the making of FUSE is an important contribution to the history and mission of SAGES and allows the reader to understand the idea, concept, realization, and implementation of the only free online educational tool for physicians on energy devices available today. FUSE is the culmination of the SAGES efforts to recognize gaps in patient safety and develop state-of-the-art educational programs to address those gaps. It is the goal of the FUSE task force to ensure that general FUSE implementation becomes multinational, involving as many countries as possible. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

23. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study

Author

Mieog, Js, Morden, Jp, Bliss, Jm, Coombes, Rc, van de Velde CJ, IES Steering Committee: Delozier, T, Veronesi, A, Vrdoljak, E, Monnier, A, Coombes, C, Nagykalnai, T, Roumen, Rm, Utracka Hutka, B, Pluzanska, A, Porpiglia, M, Genta, F, Benedetto, Chiara, Sozzani, P, Steiner, M, Rubinov, R, Leviov, M, Semiglazov, V, Fox, J, Mayordomo, Ji, Cervek, J, Sleeboom, Hp, Jassem, J, Hinton, Cp, Paulsen, Th, Guleng, Rj, Fein, L, Gutulescu, N, Florián, J, Rosso, R, Rutgers, Ej, Krzakowski, M, Pienkowski, T, Krajina, Z, Siffnerova, H, Pawlicki, M, Drosik, K, Wagnerowa, M, Brunt, M, Vukelja, S, Mitrowic, L, Cataliotti, L, Karnicka Mlodkowska, H, Bonnefoi, H, Tilch, G, Chollet, P, Patel, A, Kamby, C, Giustini, L, Acito, L, Mouridsen, H, Roche, H, De Lafontan, B, Tomczak, P, Petruzelka, L, Lortholary, A, Pacquola, Mg, Skene, A, Rici, S, Michelotti, A, Ghilezan, N, Stewart, A, Beauduin, M, Andersen, J, Vassilaros, S, Celio, L, Bajetta, E, Bastús, R, Marsland, T, Paridaens, R, Tzekova, V, Lichtenegger, W, Piersma, H, Jones, S, Holmberg, S, Verhoeven, D, Hill, A, Porcile, G, Bruno, Mf, Chernozemski, I, Coleman, R, Jadeja, J, Cohn, A, Merlano, M, Perroni, D, Di Costanzo, F, Van Bochove, A, Gerrits, Ma, Malec, V, Balil, A, Mendiola, C, Dodwell, D, Knox, R, Horgan, K, Joannides, T, Leonard, Rc, Cawthorn, Sj, Ghosh, C, Cantrell, J, Campos, D, Orti, R, Diedrich, K, Aas, H, Barnadas, A, Vila, Mm, Makris, A, Anderson, T, Chittor, S, Michel, J, Philip, P, Redmond, P, Mastboom, Wj, Nordenskjöld, B, Simmonds, P, Grieve, Rj, Tomova, A, Piot, G, Borea, G, Ucci, G, Einarsson, E, Nicholson, S, Gardiol, Ea, Kerger, J, Schlosser, J, Namer, M, Pinotti, G, Rutten, Ht, Iversen, T, Nejim, A, Dudov, A, Grundtvig, P, Lang, I, Massidda, B, Van De Velde CH, Gervasio, Mh, Tengrup, I, Tennvall, L, Goodman, S, Modgill, Vk, Vorobiof, Da, Mickiewicz, E, Chirgwin, J, Focan, C, Albin, N, Contu, Aa, Svensson, Jh, Borghede, G, Källström, Ac, Forbes, Jf, Hurtz, Hj, Tubiana Hulin, M, Viens, P, Scanni, A, Arnoldi, E, Nastasi, G, Bottini, A, Alquati, P, Muscat, V, Brincat, S, Holmen, K, Amaral, N, Moreno, I, Trask, C, Robinson, A, Mcintyre, K, Otsuka, A, Hohaus, B, Hoefig, G, Georgoulias, V, Salvagni, S, Bidin, L, Artioli, F, Engan, T, Benedikstsson, Kp, Campbell, I, Harvey, V, Zimbler, H, Mrsic Krmpotic, Z, Canon, Jl, Tchilingirov, Pv, Buser, K, Bolanca, A, Reztke, U, Rhein, U, Jouve, M, Mullins, G, Vesentini, L, Gallo, L, Merlini, L, Decensi, A, Carreca, I, Van Tienhoven, G, Börjesson, B, Hansen, J, Koza, I, Arcusa, A, Inoriza, A, Pelegri, A, Eremin, O, Modiano, Mr, Anthony, S, Donat, D, Richardet, E, Kochli, O, Zeißig, P, Gauch, G, Aabo, K, Fumoleau, P, Erdkamp, Fl, Lovén, L, Jönsson, Pe, Perren, T, Stuart, N, Galindo, E, Marek, Bj, Salmon, Jp, Dohollou, N, Thompson, R, Folco, U, Rosa, A, Tonato, M, Heijmans, Gj, Koralewski, P, Bång, H, Lescure, Ar, Carrato, A, Martin, M, Neave, F, Howell, T, Savin, M, Loesch, D, Hannois, A, Mohr, A, Laube, T, Omar, S, Bonneterre, J, Servent, V, Danese, S, Sertoli, Mr, Butzelaar, Rm, Steller, Ep, Gomez, H, Skoog, P, Alvarez, I, Aguilar, Ea, Giner, Jl, Yosef, Hm, Barrett Lee, P, Buzdar, Au, George, T, Olivaires, J, Vsianska, M, Köhler, U, Lindeløv, B, Toftdahl, Db, Nielsen, Eb, Veyret, C, Castera, D, Kerbrat, P, Vassilaros, P, Yeo, W, Boni, C, Aitini, E, Luporini, G, Herben, Mg, Espelid, H, Dahl, S, Ingvar, C, Meana, A, Pico, C, Garcia, Am, Agrawal, Rk, Gruenberg, D, Nunez de Pierro, A, Gill, G, Nogaret, Jm, Honhon, B, Wassenaar, H, Nielander, R, Warnier, P, Sessa, C, Padrik, P, Guastalla, Jp, Serin, D, Jaubert, D, Dank, M, Given, Fh, Mascia, V, De Fraia, E, Silingardi, V, Conte, Pf, Labianca, R, Tondini, C, Bagnulo, A, Gardani, G, Wils, J, Liem, G, Nuytinck, Jk, Formoe, E, Ambré, T, Alés, J, Aramburo, P, Mansi, J, Graham, J, Joffe, J, Sainsbury, J, Stone, J, Good, Rh, Cartwright, T, Werner, Id, Murray, E, Beith, J, Tigges, Fj, Bojko, P, Sandberg, E, Jensen, B, Lotz, Jp, Carney, D, Shapira, J, Neumann, A, Goldhirsch, A, Dicato, M, de Graaf, H, Maartense, E, Burghouts, J, Cassinello, J, Jones, A, Gaffney, C, Blum, R, Abdi, E, Becquart, D, Dirix, L, Janssens, J, Nmarschner, N, Blaska Jaulerry, B, Prevot, G, Mirah Lev, L, Shani, A, Baruch, Nb, Peretz, T, Gips, M, Cognetti, F, Carlini, P, Nortier, Jw, Huinink D, ten B., Roussel, Jg, Unneberg, K, Kylberg, F, Hovind, H, Nestvold, T, Fogelkvist, R, Due, J, Muller, S, Gilligan, D, Russel, S, Mcaleer, J, Yiangou, C, Foote, L, Schottstaedt, M, Holmes, Fa, Wainstein, R, Contreras, O, Martinez, J, Della Fiorentina, S, Beslija, S, Vermorken, Jb, Thirion, M, Fraikin, J, Castiglione, M, Jäger, W, Fasching, P, Fabriz, H, Neis, K, Kirschbaum, M, Labat, Jp, Dupuis, O, Bernard, J, Datchary, J, Provencal, J, Allain, P, Clerico, M, Lopez, M, Nalli, G, Aspevik, R, Fràguas, A, Curescu, S, Cuevas, Jm, Oltra, A, Bradley, C, Kapoor, R, Akbain, S, Croghan, Mk, Modiano, M, Taetle, R, Beale, P, Gobert, P, Bondue, H, Böhm, R, Møller, Ka, Brettes, Jp, Netter, G, Grogan, L, Klein, B, Botta, M, Barni, S, Van Meerwijk, I, Kåresen, R, Godes, J, Aramburo, A, Jara, C, Zanger, B, Fleagle, Jt, Greenspan, A, Marschke, R, Medgyesy, Dc, Garbo, L., CCA -Cancer Center Amsterdam, and Radiotherapy

Subjects
medicine.medical_specialty, Population, Breast Neoplasms, Disease-Free Survival, chemistry.chemical_compound, Breast cancer, Exemestane, Internal medicine, Surveys and Questionnaires, medicine, Clinical endpoint, Humans, Carpal tunnel syndrome, education, Aged, Retrospective Studies, Aged, 80 and over, education.field_of_study, business.industry, Aromatase Inhibitors, Hazard ratio, Middle Aged, medicine.disease, Carpal Tunnel Syndrome, Surgery, Musculoskeletal Abnormalities, Androstadienes, Postmenopause, Tamoxifen, Treatment Outcome, Oncology, chemistry, Hormonal therapy, Female, business, medicine.drug
Abstract

BACKGROUND: Aromatase inhibitors are more effective than is tamoxifen in prevention of breast-cancer recurrence, but at the expense of increased musculoskeletal side-effects, such as carpal tunnel syndrome. The aim of this study was to assess risk factors and the prognostic value of musculoskeletal symptoms during treatment with the steroidal aromatase inhibitor exemestane or with tamoxifen after 2-3 years of tamoxifen. METHODS: In the Intergroup Exemestane Study, postmenopausal women treated for early invasive breast cancer who remained disease free and on treatment after 2-3 years of tamoxifen were randomised to switch to exemestane or to continue tamoxifen for the remainder of the 5-year period of endocrine treatment. The primary endpoint for this retrospective analysis was occurrence of carpal tunnel syndrome and any musculoskeletal events, analysed in the safety population, which consisted of all patients who had received any trial treatment. As well as case-report forms, questionnaires were distributed retrospectively to gain more details of cases of carpal tunnel syndrome. The relation between musculoskeletal symptoms reported by 6 months from randomisation and survival from 9 months onwards was assessed by Cox proportional hazards models. The trial is registered, number ISRCTN11883920. It has completed accrual and follow-up is continuing for enrolled participants. FINDINGS: After a median follow-up of 91·0 months (IQR 83·0-99·2), carpal tunnel syndrome had been reported for 66 (2·8%) of 2319 patients in the exemestane group compared with 13 (0·6%) of 2338 in the tamoxifen group (odds ratio [OR] 5·23, 99% CI 2·39-11·49; p

Published
2012

24. Online Mediation

Author

Lodder, A.R., Bol, S.H., Brunt, G., Weij, M., Brunt, M., van Schelven, P., van der Wees, L., Institute for Informatics and Law, and Research Programmes - Law

Published
2004

26. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019)

Author

Cameron, D, primary, Barrett-Lee, P, additional, Canney, P, additional, Banerji, J, additional, Bartlett, J, additional, Bloomfield, D, additional, Bowden, S, additional, Brunt, M, additional, Earl, H, additional, Ellis, P, additional, Fletcher, M, additional, Morden, JP, additional, Robinson, A, additional, Sergenson, N, additional, Stein, R, additional, Velikova, G, additional, Verrill, M, additional, Wardley, A, additional, Coleman, R, additional, and Bliss, JM, additional

Published
2012
Full Text
View/download PDF

31. Management of breast cancer Refer women to multidisciplinary breast clinics

Author

Yarnold, J R, primary, Bliss, J M, additional, Brunt, M, additional, Earl, H, additional, Kaye, S, additional, Mason, M, additional, Mossman, J, additional, Perren, T, additional, Richards, M, additional, Clamp, S E, additional, Kunkler, I H, additional, Chetty, U, additional, Rodger, A, additional, Rothwell, I, additional, Morrison, L, additional, Statham, H, additional, Green, J, additional, and Murton, F, additional

Published
1994
Full Text
View/download PDF

38. Marine molluscs of the Cayman Islands

Author

Hess, D. F., Abbott, R. T., Hamann, J., Meyer, K., Millen, S., Gosliner, T., Sefton, N., Hanlon, Roger. T., Dumont, H. J., editor, Werger, M. J. A., editor, Brunt, M. A., editor, and Davies, J. E., editor

Published
1994
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results